Head-to-head evidence
Atirmociclib vs BGB-43395
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 · full HR+/HER2- Metastatic Breast Cancer pipeline
Atirmociclib
Developed by Pfizer
NCT06465368 · Phase 2 · completed
The study randomized 121 participants to PF-07220060 plus letrozole or letrozole alone, but it was open-label, with only the biopsy assessment performed centrally in a blinded manner. Its primary endpoint was a Ki-67-based biomarker rather than a clinical outcome, and although the reported percentages favored the combination, statistical significance for the primary comparison was not stated.
Next expected readout: December 2026 · NCT06239467 (registry estimate)
BGB-43395
Developed by BeOne Medicines
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT06756932 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atirmociclib's landscape · BGB-43395's landscape